Is HNGE a good stock to buy? We came across a bullish thesis on Hinge Health, Inc. on r/GrowthStockInvesting by Investing_Bear. In this article, we will summarize the bulls’ thesis on HNGE. Hinge Health, Inc.’s share was trading at $75.14 as of June 25th. HNGE’s forward P/E was 31.75 according to Yahoo Finance.
Image Point Fr/Shutterstock.com
Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. HNGE is emerging as one of the fastest-growing digital healthcare platforms, with its latest results reinforcing confidence in a sustained beat-and-raise trajectory. After initially guiding for fiscal year revenue of $732–742 million, representing approximately 26% year-over-year growth, the company raised its outlook after the first quarter to $798–804 million, implying 37% annual growth, while expected net income increased from $156 million to $215 million.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The strong guidance revision reflects exceptional underlying momentum and suggests further upside through additional guidance increases during the year, with revenue growth potentially exceeding 40% and approaching 50% if current trends persist. A key indicator supporting this optimism is trailing twelve-month calculated billings, which surged to $769.9 million from $671.4 million in the previous quarter, driven by a record quarterly increase of $98.5 million, significantly above historical additions.
The first-quarter performance also substantially exceeded expectations, with revenue reaching $182 million compared to guidance of $171–173 million, while adjusted net income came in at $46.2 million versus projected $30–32 million. Despite only a $9 million quarterly revenue beat, full-year guidance increased by roughly $62 million, highlighting management’s growing confidence in demand.
Profitability also improved materially, with projected 2026 operating margins rising from 21% to 26%. The investment case is further supported by an attractive balance sheet featuring $316 million in cash and no debt, an impressive 85% gross margin, and a reasonable six-times run-rate price-to-sales multiple.
While questions remain regarding the economics of its expanding medical device business and the competitive landscape, including emerging players such as Omada Health, the company’s accelerating growth, expanding profitability, and strong financial position create a compelling bullish outlook with meaningful upside potential.
Previously, we covered a bullish thesis on Doximity, Inc. (DOCS) by Business Invest in October 2024, which highlighted its dominant physician network, recurring subscription revenue, and long-term telemedicine growth opportunity. DOCS’s stock price has depreciated by approximately 54.20% since our coverage. Investing_Bear shares a similar view but emphasizes on Hinge Health’s accelerating guidance upgrades, expanding profitability, and sustained beat-and-raise execution within the digital healthcare industry.
Hinge Health, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 48 hedge fund portfolios held HNGE at the end of the first quarter which was 43 in the previous quarter. While we acknowledge the risk and potential of HNGE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HNGE and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
